{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:56:01Z","timestamp":1762005361981,"version":"3.44.0"},"reference-count":29,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,7,19]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>As we are over a year into the COVID-19 pandemic, we have made many forward strides in therapeutics. These treatments, such as monoclonal antibodies, have help mitigate the detrimental and often fatal consequences of COVID-19. The current indication for the use of monoclonal antibodies is mild to moderate COVID-19 infection within 10 days of symptom onset in those who are at high risk of progression to severe disease. However, their role in patients with prolonged symptoms is not clear. We present a unique case of monoclonal antibodies use after 54 days of symptom onset in an immunosuppressed patient with persistent COVID-19 infection despite standard treatment. This case illustrates the potential use of monoclonal antibodies outside of the current recommended therapeutic window in immunosuppressed patients, who may have difficulty with viral clearance.<\/jats:p>","DOI":"10.1136\/bcr-2021-243469","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T12:06:07Z","timestamp":1627992367000},"page":"e243469","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab"],"prefix":"10.1136","volume":"14","author":[{"given":"Carlos X","family":"Rabascall","sequence":"first","affiliation":[{"name":"Pulmonary, Critical Care and Sleep Medicine, Northwell Health, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Becky X","family":"Lou","sequence":"additional","affiliation":[{"name":"Pulmonary, Critical Care and Sleep Medicine, Northwell Health, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brianne","family":"Navetta-Modrov","sequence":"additional","affiliation":[{"name":"Rheumatology, Allergy and Immunology, Stony Brook University Renaissance School of Medicine, Stony Brook, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella S","family":"Hahn","sequence":"additional","affiliation":[{"name":"Pulmonary, Critical Care and Sleep Medicine, Northwell Health, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"2025082710034683000_14.8.e243469.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30120-1"},{"key":"2025082710034683000_14.8.e243469.2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"2025082710034683000_14.8.e243469.3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jama.2020.24415","article-title":"An EUA for Bamlanivimab-A monoclonal antibody for COVID-19","volume":"325","year":"2021","journal-title":"JAMA"},{"key":"2025082710034683000_14.8.e243469.4","unstructured":"L J . New name and packaging for Regeneron COVID-19 monoclonal antibodies (casirivimab with imdevimab) to be administer together: REGEN-COV\u2122. In: Administration USFaD. Tarrytown, NY: Regeneron, 2021. https:\/\/www.fda.gov\/media\/145611\/download"},{"key":"2025082710034683000_14.8.e243469.5","unstructured":"C-TG P , Disease C . COVID-19) treatment guidelines: National Institutes of health 2019."},{"key":"2025082710034683000_14.8.e243469.6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1084822320964196","article-title":"\u201cAmbulatory Management of Moderate to High Risk COVID-19 Patients: The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol\u201d","volume":"33","author":"Lisker","year":"2021","journal-title":"Home Health Care Manag Pract"},{"key":"2025082710034683000_14.8.e243469.7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bjh.16935","article-title":"Poor outcome and prolonged persistence of SARS\u2010CoV\u20102 RNA in COVID\u201019 patients with haematological malignancies; King\u2019s College Hospital experience","volume":"190","author":"Shah","year":"2020","journal-title":"Br J Haematol"},{"key":"2025082710034683000_14.8.e243469.8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bjh.16852","article-title":"Clinical outcome of coronavirus disease 2019 in haemato\u2010oncology patients","volume":"190","author":"Aries","year":"2020","journal-title":"Br J Haematol"},{"key":"2025082710034683000_14.8.e243469.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6"},{"key":"2025082710034683000_14.8.e243469.10","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in persons with haematological cancers","volume":"34","author":"He","year":"2020","journal-title":"Leukemia"},{"key":"2025082710034683000_14.8.e243469.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2009567"},{"key":"2025082710034683000_14.8.e243469.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102306","article-title":"COVID-19 in 7 multiple sclerosis patients in treatment with anti-CD20 therapies","volume":"44","author":"Meca-Lallana","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2025082710034683000_14.8.e243469.13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16896"},{"key":"2025082710034683000_14.8.e243469.14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01578","article-title":"Prolonged course of COVID-19-Associated pneumonia in a B-cell depleted patient after rituximab","volume":"10","author":"Kos","year":"2020","journal-title":"Front Oncol"},{"key":"2025082710034683000_14.8.e243469.15","doi-asserted-by":"crossref","unstructured":"Schulze-Koops H , Krueger K , Vallbracht I . Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 2020.doi:10.1136\/annrheumdis-2020-218075","DOI":"10.1136\/annrheumdis-2020-218075"},{"key":"2025082710034683000_14.8.e243469.16","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00296-020-04699-x","article-title":"High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study","volume":"40","author":"Loarce-Martos","year":"2020","journal-title":"Rheumatol Int"},{"key":"2025082710034683000_14.8.e243469.17","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-64"},{"key":"2025082710034683000_14.8.e243469.18","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-017-0100-y"},{"key":"2025082710034683000_14.8.e243469.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.05.002"},{"key":"2025082710034683000_14.8.e243469.20","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.clml.2020.08.017","article-title":"Persistent COVID-19 pneumonia and failure to develop Anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma","volume":"20","author":"Yasuda","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025082710034683000_14.8.e243469.21","unstructured":"Benucci M , Quartuccio L , Li Gobbi F . Ann Rheum Dis 2020."},{"key":"2025082710034683000_14.8.e243469.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2009.10.004"},{"key":"2025082710034683000_14.8.e243469.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.8259"},{"key":"2025082710034683000_14.8.e243469.24","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1093\/cid\/ciaa1199","article-title":"College of American pathologists (CAP) microbiology Committee perspective: caution must be used in interpreting the cycle threshold (CT) value","volume":"72","author":"Rhoads","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025082710034683000_14.8.e243469.25","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01695-20","article-title":"Challenges and controversies to testing for COVID-19","volume":"58","author":"Binnicker","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2025082710034683000_14.8.e243469.26","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/bjh.17266","article-title":"Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies","volume":"192","author":"Betrains","year":"2021","journal-title":"Br J Haematol"},{"key":"2025082710034683000_14.8.e243469.27","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"2025082710034683000_14.8.e243469.28","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/bjh.16981","article-title":"Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery","volume":"190","author":"Clark","year":"2020","journal-title":"Br J Haematol"},{"key":"2025082710034683000_14.8.e243469.29","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg Microbes Infect"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:03:54Z","timestamp":1756314234000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,3]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/bcr-2021-243469"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243469","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}